Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Share-based Compensation (2019 - 2025)

Historic Share-based Compensation for Bolt Biotherapeutics (BOLT) over the last 7 years, with Q3 2025 value amounting to $407000.0.

  • Bolt Biotherapeutics' Share-based Compensation fell 6293.26% to $407000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 million, marking a year-over-year decrease of 6475.34%. This contributed to the annual value of $7.4 million for FY2024, which is 1968.99% down from last year.
  • Per Bolt Biotherapeutics' latest filing, its Share-based Compensation stood at $407000.0 for Q3 2025, which was down 6293.26% from $625000.0 recorded in Q2 2025.
  • Over the past 5 years, Bolt Biotherapeutics' Share-based Compensation peaked at $2.9 million during Q1 2022, and registered a low of $407000.0 during Q3 2025.
  • Moreover, its 5-year median value for Share-based Compensation was $2.1 million (2021), whereas its average is $1.9 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first soared by 83733.33% in 2021, then tumbled by 7787.61% in 2025.
  • Quarter analysis of 5 years shows Bolt Biotherapeutics' Share-based Compensation stood at $2.1 million in 2021, then decreased by 0.89% to $2.1 million in 2022, then dropped by 2.59% to $2.1 million in 2023, then plummeted by 42.84% to $1.2 million in 2024, then tumbled by 65.57% to $407000.0 in 2025.
  • Its last three reported values are $407000.0 in Q3 2025, $625000.0 for Q2 2025, and $709000.0 during Q1 2025.